辛伐他丁联合小剂量大环内酯类药物治疗慢性阻塞性肺疾病的疗效评价

摘要

Objective To investigate simvastatin combined with low dose macrolides in chronic obstructive pulmonary disease in patients with acute exacerbation, lung function and quality of life . Methods 108 cases of chronic obstructive pulmonary disease were randomly divided into low-dose macrolide therapy group (A), simvastatin treatment group (B) and low-dose simvastatin macrolide combination therapy group (C group ). A group was given roxithromycin treatment , B group received simvastatin , C group of patients given roxithromycin simvastatin treatment. Record three groups of patients within 12 weeks the number of exacerbations, and three groups of patients before and after treatment of respiratory symptoms , SGEQ score, FEV1%was measured before and after treatment to compare the quality of life . Results C group, 2 cases of acute exacerbation of 12 weeks , A group of eight cases of acute attacks;C group of six cases of acute episodes . The three groups of patients as well as improvement in symptoms after treatment FEV1%, SCRQ scores were compared , the difference was statistically significant (P<0.05). Conclusions Simvastatin combined with low dose macrolide treatment of chronic obstructive pulmonary disease can significantly improve lung function in patients with COPD , reducing the number of exacerbations , improve the patient's quality of life.%目的：探讨辛伐他丁联合小剂量大环内酯类药物对慢性阻塞性肺疾病患者的急性发作、肺功能及生活质量的影响。方法将108例慢性阻塞性肺疾病患者随机分成小剂量大环内酯类治疗组（A组）、辛伐他汀治疗组（B组）和小剂量大环内酯类联合辛伐他汀治疗组（C组）。A组给予罗红霉素治疗，B组给予辛伐他汀治疗，C组患者给与罗红霉素联合辛伐他汀治疗。记录三组患者12周内急性发作的人数，并对三组患者治疗前后的呼吸系统症状、SGEQ评分、治疗前后的FEV1%测定的生活质量进行比较。结果 C组12周内急性发作2例，A组急性发作8例；C组急性发作6例。将三组患者治疗之后症状改善方面以及FEV1%、SCRQ评分进行比较，差异有统计学意义（P＜0.05）。结论辛伐他汀联合小剂量大环内酯类药物治疗慢性阻塞性肺疾病能明显改善COPD患者的肺功能、减少急性发作的次数、提高患者的生活质量。